Palvella Therapeutics (PVLA)
Develops topical QTORIN candidates for serious rare skin diseases and vascular malformations.
Something off on this page? Send us feedback.
Develops topical QTORIN product candidates for rare skin diseases and vascular malformations with no approved products yet. The pipeline centers on QTORIN rapamycin, with QTORIN pitavastatin earlier in development, and the business relies on clinical progress, regulatory approval, third-party execution, and formulation intellectual property.
Develops topical QTORIN formulations for serious rare skin diseases and vascular malformations, with no approved commercial products or product revenue yet. The lead program is QTORIN rapamycin for microcystic lymphatic malformations, with additional rapamycin programs for cutaneous venous malformations and clinically significant angiokeratomas.
The pipeline also includes QTORIN pitavastatin for disseminated superficial actinic porokeratosis. Operations are concentrated in the United States through a small Wayne, Pennsylvania-based clinical-stage organization, and the company reports one operating segment.
Execution depends on clinical development, regulatory review, third-party manufacturers and research partners, and protection of formulation intellectual property around active ingredients that are not themselves patent-protected. Future revenue depends on approval and commercialization of product candidates.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 21, 2026 | Chardan Capital | Reiterate | Rating: —Target: $210 | Target: $240 |
| Aug 5, 2026 | Truist Financial | Target | Target: $210 | Target: $207 |
| Aug 5, 2026 | Canaccord Genuity | Target | Target: $204 | Target: $232 |
| Jul 22, 2026 | H.C. Wainwright | Reiterate | Rating: —Target: $255 | Target: $270 |
| May 12, 2026 | Stephens | Target | Target: — | Target: $220 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $250.6M · Total debt $535.0K · Total assets $253.5M · Shareholders' equity $216.9M
- Revenue
- $0
- Operating income
- −$21.4M
- Net income
- −$21.9M
No dividends on record.
| Institutions | ≈ 96.62% | 13.92M shares | |
|---|---|---|---|
| 208 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 8.10% | 1.17M shares | |
| 6 holders · as of Sep 15, 2026 | |||
| Strategic holders | 6.95% | 1.00M shares | |
| 2 holders · as of Aug 10, 2026 | |||
| Adds to | 111.67% | ||
14.41M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 111.67%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Suvretta Capital Management, LLCInstitution | 7.88% | 1.14M | as of Jun 30, 2026 |
Prudential Financial IncStrategic | 6.68% | 962,374 | filed Aug 10, 2026 |
Jennison Associates LLCInstitution | 6.67% | 960,619 | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 6.37% | 918,357 | as of Jun 30, 2026 |
Frazier Life Sciences Management, L.P.Institution | 6.12% | 882,400 | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 16, 2026 | Kathleen Goin | officer: Chief Operating Officer | −4,302 | $152.24 |
| Sep 15, 2026 | George M. Jenkins | director | −1,777 | $150.14 |
| Sep 14, 2026 | George M. Jenkins | director | −13,352 | $151.96 |
| Sep 11, 2026 | George M. Jenkins | director | −12,371 | $151.28 |
| Sep 2, 2026 | Christopher P. Kiritsy | director | −313 | $157.00 |
- Novartis (ADR)
Approved PROS vascular-anomaly therapy with Vijoice
- Protara Therapeutics
Phase 2 lymphatic-malformation program with TARA-002
- Relay Therapeutics
PI3Kalpha vascular-anomaly program with zovegalisib
- Krystal Biotech
Topical rare-skin gene therapy commercialized as VYJUVEK
- Pfizer
Established oral sirolimus franchise with Rapamune
- Abeona Therapeutics
Autologous rare-skin gene therapy commercialized as ZEVASKYN
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Palvella Therapeutics | $149.81 | −5.26% | $2.27B | — | — | — | — |
| Novartis (ADR) | $142.22 | +0.66% | $268.53B | 21.3 | 15.1 | 4.8 | +0.9% |
| Protara Therapeutics | $3.50 | −4.98% | $206.8M | — | — | — | — |
| Relay Therapeutics | $17.53 | −9.41% | $4.24B | — | — | 409.7 | −48.3% |
| Krystal Biotech | $341.93 | −2.55% | $10.34B | 44.0 | 40.2 | 23.5 | +24.1% |
| Pfizer | $28.04 | +0.38% | $159.19B | 36.9 | 10.0 | 2.5 | +2.6% |
| Abeona Therapeutics | $5.70 | −2.15% | $331.7M | — | — | 13.0 | +2,745.0% |
| Median | 36.9 | 15.1 | 13.0 | +2.6% |